GlaxoSmithKline Pharmaceuticals
add_icon

GlaxoSmithKline Pharmaceuticals

2,377.40
-21.30
(-0.89%)
Market Cap
40,274.59 Cr
PE Ratio
42.54
Volume
62,041.00
Day High - Low
2,392.80 - 2,358.00
52W High-Low
3,515.70 - 1,921.00
ann
There are new updates from the company1 day ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
40,274.59 Cr
EPS
54.76
PE Ratio
42.54
PB Ratio
23.80
Book Value
100.80
EBITDA
1,323.30
Dividend Yield
2.25 %
Industry
Healthcare
Return on Equity
47.54
Debt to Equity
0.01
Analyst Rating and Forecast
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+50.00 %
+50.00 %
Hold
Hold+50.00 %
+50.00 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
negative
GlaxoSmithKline Pharmaceuticals receives GST demand order of ₹35.07 lakhs from Maharashtra authorities for FY 2021-22, related to credit mismatch issues with suppliers.
negative
GlaxoSmithKline Pharmaceuticals receives GST demand order worth ₹8.57 crores from Karnataka authorities for FY 2021-22, related to GST rates on certain products.
neutral
GlaxoSmithKline Pharmaceuticals responds to exchange queries about significant trading volume increase, confirming all regulatory disclosures are up-to-date and attributing surge to market forces.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,728.10
#1 4,14,629.08
40.31
#1 54,729.00
9.71
#1 10,980
2.89
52.13
6,572.50
1,74,479.22
70.47
9,712.00
18.67
2,191
35.10
59.83
3,964.00
1,34,159.77
63.66
11,539.40
6.99
1,911
30.46
70.17
1,465.20
1,18,354.72
21.71
28,409.50
7.12
5,291
3.71
36.98
1,207.30
1,00,764.92
#1 17.57
33,741.20
16.73
5,725
-0.38
29.23
2,179.50
99,559.30
23.02
22,909.50
13.74
3,306
#1 72.75
65.89
2,192.60
90,511.64
52.52
12,744.20
#1 20.90
2,007
-21.05
56.26
891.00
89,655.45
18.16
23,511.00
18.55
4,615
34.60
41.07
1,191.20
69,185.09
20.49
32,345.60
9.43
3,484
3.81
51.02
5,749.00
68,737.92
28.76
13,458.30
3.70
2,216
10.98
62.82
Growth Rate
Revenue Growth
8.91 %
Net Income Growth
57.22 %
Cash Flow Change
121.62 %
ROE
43.24 %
ROCE
42.20 %
EBITDA Margin (Avg.)
17.79 %

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
754
831
871
823
819
1,299
795
803
707
888
834
785
764
964
838
2,132
776
939
826
826
815
985
833
962
850
1,050
985
1,015
849
1,016
Expenses
608
663
688
588
623
688
1,408
602
535
739
611
707
586
678
636
634
596
660
585
618
618
668
751
673
584
689
658
641
554
644
EBITDA
145
168
183
236
196
611
-613
201
172
150
223
78
178
286
202
1,497
180
279
241
208
198
318
83
290
266
361
327
374
295
372
Operating Profit %
17 %
19 %
17 %
22 %
21 %
22 %
-81 %
22 %
18 %
16 %
23 %
5 %
18 %
27 %
22 %
22 %
20 %
28 %
27 %
22 %
19 %
30 %
7 %
28 %
28 %
32 %
31 %
34 %
31 %
34 %
Depreciation
11
12
12
14
19
23
18
23
22
22
18
18
18
17
18
15
16
16
16
17
16
18
17
18
16
17
19
15
16
17
Interest
0
0
0
0
1
1
3
2
1
1
1
1
1
0
1
0
1
0
0
1
0
0
0
1
0
0
0
1
0
1
Profit Before Tax
134
157
171
222
176
587
-634
177
149
127
204
60
160
268
184
1,482
163
262
224
190
181
299
65
271
249
344
308
359
279
354
Tax
50
56
57
75
63
85
27
39
38
51
48
45
39
64
34
263
44
69
60
57
49
82
20
76
67
91
78
96
74
97
Net Profit
84
101
114
147
114
503
-661
138
111
77
157
14
121
204
150
1,219
119
193
165
133
132
218
46
195
182
253
230
263
205
258
EPS in ₹
9.93
5.95
6.71
8.67
6.70
29.68
-39.03
8.15
6.54
4.51
10.26
0.85
7.14
12.06
8.87
71.96
7.04
11.42
9.71
7.41
7.04
12.84
9.89
11.37
10.76
14.67
13.57
15.52
12.10
15.07

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
3,216
3,055
3,004
3,948
3,911
3,136
3,115
4,633
3,327
3,557
4,108
Fixed Assets
123
210
258
325
432
758
387
331
330
321
284
Current Assets
2,587
2,174
1,674
2,186
2,010
1,775
2,203
3,708
2,494
2,798
3,410
Capital Work in Progress
115
268
606
923
1,003
120
13
31
20
14
14
Investments
0
0
0
0
0
0
0
366
518
813
1,118
Other Assets
2,977
2,577
2,140
2,700
2,477
2,257
2,715
3,907
2,458
2,408
2,692
Total Liabilities
3,216
3,055
3,004
3,948
3,911
3,136
3,115
4,633
3,327
3,557
4,108
Current Liabilities
1,107
579
720
1,600
1,454
1,024
1,355
1,698
1,326
1,525
1,905
Non Current Liabilities
280
292
277
290
317
291
282
272
259
254
252
Total Equity
1,829
2,183
2,007
2,057
2,140
1,821
1,478
2,663
1,741
1,778
1,951
Reserve & Surplus
1,744
2,099
1,922
1,973
1,970
1,651
1,309
2,494
1,572
1,608
1,782
Share Capital
85
85
85
85
169
169
169
169
169
169
169

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
21
-0
24
62
-102
6
300
-119
-251
29
475
Investing Activities
180
499
301
-104
-153
-57
418
-406
808
9
-46
Operating Activities
338
139
234
473
410
491
578
811
484
582
1,290
Financing Activities
-497
-638
-511
-307
-358
-428
-696
-524
-1,543
-562
-769

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
75.00 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
3.48 %
4.02 %
4.36 %
4.50 %
4.52 %
4.89 %
4.80 %
DIIs
5.31 %
5.51 %
5.50 %
5.61 %
5.61 %
4.08 %
10.45 %
10.28 %
10.30 %
10.23 %
10.01 %
8.53 %
7.90 %
7.50 %
7.34 %
7.30 %
7.79 %
7.70 %
7.75 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
11.02 %
10.86 %
10.83 %
10.67 %
10.41 %
10.41 %
10.40 %
10.56 %
10.54 %
10.57 %
10.62 %
11.08 %
11.27 %
11.15 %
10.97 %
10.96 %
10.60 %
10.32 %
10.34 %
Others
8.67 %
8.62 %
8.67 %
8.73 %
8.98 %
10.51 %
4.15 %
4.16 %
4.16 %
4.20 %
4.37 %
5.38 %
2.35 %
2.33 %
2.33 %
2.23 %
2.09 %
2.09 %
2.11 %
No of Share Holders
1,19,951
1,20,476
1,21,445
1,23,480
1,10,141
1,12,964
1,16,651
1,20,127
1,20,415
1,19,032
1,15,266
1,14,663
1,18,994
1,18,515
1,19,228
1,19,625
1,21,885
1,23,629
1,22,904

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 30 35 20 40 30 90 32 32 54 0.00
Dividend Yield (%) 2.87 2.7 1.59 2.78 1.8 7.05 1.64 1.11 2.25 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
09 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
09 Feb 2026 2,457.05 2,398.70
13 Sept 2018 BONUS Bonus
1:1
11 Sept 2018 1,726.60 1,724.70
20 Jul 2021 DIVIDEND Dividend
30.00 /share
19 Jul 2021 1,518.15 1,607.55
08 Jul 2022 DIVIDEND Dividend
60.00 /share
07 Jul 2022 1,493.30 1,505.90
08 Jul 2022 DIVIDEND Dividend
30.00 /share
07 Jul 2022 1,493.30 1,505.90
26 Jul 2022 ANNUAL GENERAL MEETING Annual General Meeting
NA
26 Jul 2022 1,493.30 1,493.85
30 Jun 2023 DIVIDEND Dividend
32.00 /share
30 Jun 2023 1,289.55 1,438.20
31 May 2024 DIVIDEND Dividend
32.00 /share
31 May 2024 2,023.85 2,593.00
28 Jun 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
28 Jun 2024 2,023.85 2,677.55
29 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
29 Oct 2024 2,630.85 2,644.65
07 Nov 2024 DIVIDEND Dividend
12.00 /share
07 Nov 2024 2,644.65 2,632.20
14 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Feb 2025 2,077.20 1,998.80
13 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 May 2025 2,928.60 2,721.25
30 May 2025 DIVIDEND Dividend
42.00 /share
30 May 2025 2,721.25 3,263.40
27 Jun 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
27 Jun 2025 2,721.25 3,301.90
01 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
01 Aug 2025 3,262.85 3,158.15
06 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Nov 2025 2,758.10 2,661.50

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20181 day ago
Board Meeting Intimation for Un-Audited Financial Results For The Third Quarter & Nine Months Ended 31St December 2025.2 days ago
Disclosure Under Regulation 308 days ago
Disclosure Under Regulation 308 days ago
Volume Movement Letter8 days ago
Clarification sought from GlaxoSmithKline Pharmaceuticals Ltd9 days ago
Closure of Trading WindowDec 23, 2025
Disclosure Under Regulation 30Dec 22, 2025
Disclosure Under Regulation 30Dec 18, 2025
Disclosure Under Regulation 30Dec 12, 2025
Disclosure Under Regulation 30Nov 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 06, 2025
Announcement under Regulation 30 (LODR)-AcquisitionNov 06, 2025
Results Ended Quater September 2025Nov 06, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 06, 2025
Board Meeting Outcome for OutcomeNov 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 30, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementOct 29, 2025
Board Meeting Intimation for Approval Of Un-Audited Financial Results For The Quarter & Half Year Ended 30Th September 2025.Oct 27, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Closure of Trading WindowSep 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 25, 2025
Disclosure Under Regulation 30Sep 08, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 25, 2025
Disclosure Under Regulation 30Aug 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 08, 2025
Disclosure Under Regulation 30Aug 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 04, 2025
Rumour verification - Regulation 30(11)Aug 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 02, 2025
Clarification sought from GlaxoSmithKline Pharmaceuticals LtdAug 01, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 01, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 01, 2025
Board Meeting Outcome for Outcome Of MeetingAug 01, 2025
Quarter Ended 30Th June 2025Aug 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 28, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 23, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 09, 2025
Board Meeting Intimation for Board Meeting Intimation Jul 04, 2025
Outcome Of AGMJun 27, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportJun 27, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMJun 27, 2025
Disclosure Under Regulation 30Jun 27, 2025
Closure of Trading WindowJun 26, 2025
Analyst MeetJun 20, 2025
Disclosure Under Regulation 30Jun 19, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
SBI Mid Cap Direct Plan-Growth
0.00%
-1200000
-1.32%
-1.36%
Kotak Large & Midcap Fund Direct-Growth
0.00%
-1100000
-0.94%
-0.98%
SBI Dividend Yield Fund Direct - Growth
0.00%
-450000
-1.26%
-1.27%
Kotak Flexicap Fund Direct-Growth
0.00%
-399331
-0.18%
-0.19%
Bajaj Finserv Flexi Cap Fund Direct-Growth
0.00%
-272080
-1.11%
-1.18%
Bandhan ELSS Tax Saver Fund Direct Plan-Growth
0.00%
-230000
-0.81%
-0.80%
Aditya Birla Sun Life ELSS Tax Saver Direct-Growth
0.24%
-183254
-0.31%
-0.65%
Mahindra Manulife Small Cap Fund Direct - Growth
0.00%
-182918
-1.11%
-1.11%
ICICI Prudential Smallcap Fund Direct Plan-Growth
0.51%
174944
0.51%
0.51%
Edelweiss Balanced Advantage Fund Direct-Growth
0.00%
-107514
-0.21%
-0.21%
Bandhan Multi Cap Fund Direct-Growth
0.00%
-105000
-0.93%
-0.78%
Kotak Manufacture in India Fund Direct - Growth
0.00%
-100000
-1.05%
-1.00%
Bajaj Finserv Large and Mid Cap Fund Direct-Growth
0.00%
-93985
-1.05%
-1.10%
Tata India Pharma & Healthcare Fund Direct-Growth
0.00%
-85544
-1.64%
0.00%
Bajaj Finserv Multi Asset Allocation Fund Direct-Growth
0.00%
-78345
-1.51%
-1.60%
DSP Quant Fund Direct - Growth
0.00%
-64413
-1.78%
-1.83%
Mahindra Manulife Flexi Cap Fund Direct - Growth
0.00%
-55094
-0.88%
-0.92%
Kotak ESG Exclusionary Strategy Fund Direct - Growth
0.00%
-55000
-1.63%
-1.66%
Bajaj Finserv Multi Cap Fund Direct-Growth
0.00%
-52275
-1.25%
-1.24%
Mahindra Manulife Business Cycle Fund Direct - Growth
0.00%
-41937
-0.83%
-0.85%
Edelweiss Nifty Midcap150 Momentum 50 Index Fund Direct - Growth
0.00%
-37425
-0.70%
-0.74%
Sundaram Multi-Factor Fund Direct-Growth
0.00%
-34669
-0.89%
-2.09%
Mahindra Manulife ELSS Tax Saver Fund Direct -Growth
0.00%
-32325
-0.85%
-0.87%
DSP Nifty Midcap 150 Quality 50 Index Fund Direct - Growth
0.00%
-31866
-1.69%
-1.73%
Bajaj Finserv Balanced Advantage Fund Direct-Growth
0.00%
-30224
-0.58%
-0.58%

Technical Indicators

RSI(14)
Neutral
37.28
ATR(14)
Volatile
59.65
STOCH(9,6)
Neutral
54.13
STOCH RSI(14)
Neutral
67.90
MACD(12,26)
Bearish
-5.07
ADX(14)
Strong Trend
30.04
UO(9)
Bearish
47.89
ROC(12)
Downtrend And Accelerating
-4.94
WillR(14)
Oversold
-83.00

About GlaxoSmithKline Pharmaceuticals

GlaxoSmithKline Pharmaceuticals Limited is an Indian subsidiary of UK-based GSK Plc, engaged in manufacturing, distributing, and trading pharmaceuticals. The company operates in three main product areas: vaccines, specialty medicines, and general medicines. It has manufacturing facilities in Nashik and Thane, with a clinical development center in Bangalore. The company's portfolio...more
Chairperson NameRenu S Karnad